PBPH vs. CNCR

Last updated Jun 4, 2026

PBPH (Portfolio Building Block World Pharma and Biotech Index ETF) and CNCR (Loncar Cancer Immunotherapy ETF) are both Health & Biotech Equities funds - PBPH tracks the BITA Global Pharma and Biotech Select Index while CNCR tracks the Loncar Cancer Immunotherapy Index. Both are passively managed. PBPH charges 0.13%/yr vs 0.79%/yr for CNCR.

Performance

PBPH vs. CNCR - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) and Loncar Cancer Immunotherapy ETF (CNCR). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

PBPH

• 1D: 0.58%
• 1M: 0.07%
• YTD: -1.13%
• 6M: -0.02%
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

CNCR

• 1D: 0.00%
• 1M: 0.00%
• YTD: —
• 6M: —
• 1Y: —
• 3Y*: —
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

PBPH vs. CNCR - Yearly Performance Comparison

	2026 (YTD)
PBPH Portfolio Building Block World Pharma and Biotech Index ETF	-7.48%
CNCR Loncar Cancer Immunotherapy ETF	0.00%

Return for Risk

PBPH vs. CNCR - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Portfolio Building Block World Pharma and Biotech Index ETF (PBPH) and Loncar Cancer Immunotherapy ETF (CNCR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.

Sharpe Ratios by Period

	PBPH	CNCR	Difference
Sharpe Ratio (All Time) Calculated using the full available price history	-0.04	—	—

Drawdowns

PBPH vs. CNCR - Drawdown Comparison

The maximum PBPH drawdown since its inception was -11.10%, which is greater than CNCR's maximum drawdown of 0.00%. Use the drawdown chart below to compare losses from any high point for PBPH and CNCR.

Drawdown Indicators

	PBPH	CNCR	Difference
Max Drawdown Largest peak-to-trough decline	-11.10%	0.00%	-11.10%
Current Drawdown Current decline from peak	-8.69%	0.00%	-8.69%
Average Drawdown Average peak-to-trough decline	-4.23%	0.00%	-4.23%

Volatility

Volatility by Period

	PBPH	CNCR	Difference
Volatility (1Y) Calculated over the trailing 1-year period	16.78%	0.00%	+16.78%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	16.78%	0.00%	+16.78%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	16.78%	0.00%	+16.78%

PBPH vs. CNCR - Expense Ratio Comparison

PBPH has a 0.13% expense ratio, which is lower than CNCR's 0.79% expense ratio.

Dividends

PBPH vs. CNCR - Dividend Comparison

PBPH's dividend yield for the trailing twelve months is around 0.09%, while CNCR has not paid dividends to shareholders.

Position	TTM	2025
CNCR Loncar Cancer Immunotherapy ETF	0.00%	0.00%
PBPH Portfolio Building Block World Pharma and Biotech Index ETF	0.09%	0.09%

Frequently Asked Questions

Which ETF is better, PBPH or CNCR?

On fees, PBPH is cheaper at 0.13% per year. The better choice depends on whether you care most about return, fees, risk, or income.

Which ETF is cheaper, PBPH or CNCR?

PBPH is cheaper with a 0.13% expense ratio, compared with 0.79% for CNCR.

Which ETF pays a higher dividend yield, PBPH or CNCR?

PBPH has the higher dividend yield at 0.09%, compared with 0.00% for CNCR.

What is the main difference between PBPH and CNCR?

PBPH tracks BITA Global Pharma and Biotech Select Index, while CNCR tracks Loncar Cancer Immunotherapy Index. They also come from different issuers: Portfolio Building Block and Exchange Traded Concepts. Their fees differ too: 0.13% for PBPH and 0.79% for CNCR.